Ulcerative colitis

Accurate methods and dataset labels matter for researchers reproducing transcriptomic analyses and for clinicians interpreting translational implications. The corrigendum clarifies which datasets and experimental models...

Persistent or worsening colonic dilatation in ulcerative colitis can reflect severe, possibly irreversible bowel‑wall damage even when classic signs of toxic megacolon are absent. Recognizing this may prompt timely...

Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis and Complications. The original article is from Cureus.

Defining whether IBD therapies prevent long-term damage matters to patients and clinicians because it affects treatment goals and long-term care planning.

Better imaging of intestinal cells could help researchers find previously unseen changes in the gut barrier that contribute to IBD, which might eventually guide more targeted therapies or diagnostics.

The work explores fundamental mechanisms by which inflammation may impair colonic epithelial identity and barrier integrity in ulcerative colitis — knowledge that could lead to new targets to improve mucosal healing.

This project investigates how estrogen receptor signaling in intestinal epithelial cells drives sex-specific responses to injury and inflammation that may influence ulcerative colitis risk and progression.

Patients and clinicians struggle to predict relapse in ulcerative colitis because current endoscopic, histologic, and noninvasive biomarkers are imperfect. A tissue-based imaging and spatial-omics approach could identify...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Foods (Basel, Switzerland).

The study links a common dietary compound (oxalate) to worsened intestinal inflammation in IBD and identifies reduced gut oxalate-transport gene activity and microbiome differences as possible mechanisms—findings that...

The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...

People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...

A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastro hep...

Targeting IL‑1 is a promising route to reduce gut inflammation in IBD, but existing IL‑1 drugs face delivery and stability challenges. Nanocarriers could improve how these agents reach inflamed intestinal tissue, which...

Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...

Researchers identified COPZ1 as a shared ferroptosis-related hub gene in Crohn’s disease, ulcerative colitis, and periodontitis, which could point to a new molecular pathway linking gut and oral inflammation and a...

The mucus layer and goblet cells are central to colonic barrier function; understanding goblet cell diversity and plasticity could point to new ways to restore the mucus barrier in UC and improve disease control.

Cure8 found this source from Gastroenterology report, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. Open the original article for the...

Severe UC flares can produce extreme but reversible hyperglycemia that may look like new-onset diabetes, so patients and clinicians should monitor and re-evaluate glucose over time rather than assuming a permanent...

The work highlights a widespread tire-derived contaminant (6PPDQ) that may worsen colitis in a mouse model by disturbing key molecular pathways; this raises questions about whether environmental pollutants could...

The study suggests a common plant compound (oxalate) may build up in the intestines of people with IBD because transporter proteins are reduced, potentially worsening inflammation. If confirmed, this could influence...

People with IBD in this study had much worse quality of life and a high burden of other medical and mental-health conditions; addressing these comorbidities could improve daily functioning and outcomes.

The study links a common dietary flavonoid, epicatechin, to restoration of a protective ILC3 subset and mucosal repair in mouse colitis via a defined molecular pathway. This could point to new therapeutic targets for...

A single agent that both highlights inflamed colon tissue on MRI and delivers anti-inflammatory therapy could improve how ulcerative colitis is monitored and treated, reducing reliance on metal contrast agents.

This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Pakistan Veterinary Journal.

Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...

Depression and GI diseases often co-occur; knowing which tends to appear first — and that this varies by subtype — can help clinicians prioritize screening and integrated care.

The study identifies specific small molecules and polysaccharide features in Atractylodes macrocephala that correlated with reduced inflammation in a mouse model of ulcerative colitis, which could guide future...

Cure8 found this source from Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, but the page could not be read reliably yet....

Genetic variation in MYO9B has been linked to Crohn’s disease, ulcerative colitis, and celiac disease. This study suggests a plausible epithelial-cell mechanism — altered microvilli and RhoA signaling — that could help...

Monogenic causes (especially IL-10RA mutations) are common in infant-onset IBD and are linked to more severe disease and higher mortality; early genetic testing and consideration of HSCT may change prognosis.

A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.

A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...

IBD patients and clinicians may see more treatment options in the future if Lilly’s pipeline programs (notably mirikizumab and oral α4β7 inhibitors) succeed.

Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...

The paper describes a new nanodelivery method that improves targeted delivery of 5‑ASA in preclinical models, which could eventually address limitations of oral mesalazine formulations for colonic inflammation.

If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.

Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....

This study suggests airborne, soil-associated microbes can change the gut microbiome and reduce colitis severity in mice — a possible explanation for lower ulcerative colitis rates in rural areas. If similar effects...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Nanomedicine.

If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.

This trial tests a new oral drug, SAR441566, as a potential treatment for moderate-to-severe ulcerative colitis. Results could affect future treatment options if the drug is effective and safe.

This trial tests a new oral drug for moderate to severe ulcerative colitis with a short (12-week) primary endpoint; people with active UC may be interested in emerging treatment options and clinical trial opportunities.

Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent...

Label changes affect how balsalazide is prescribed and monitored for people with ulcerative colitis. The update highlights safety risks—especially kidney, liver, and hypersensitivity concerns—and reinforces age- and...

This study suggests a new preclinical approach to help the gut lining heal in ulcerative colitis by targeting macrophage metabolism (myeloid AMPK) rather than directly treating epithelial cells. That could matter for...